Who
Ann L. Lee
Chief Technical Officer
Company insider
Files Form 4 as: Chief Technical Officer, Prime Medicine; EVP, Technical Operations, Juno Therapeutics.
In numbers
- Trades disclosed
- 20
- Buys
- 1
- Sells
- 0
- Bought
- $113K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 25 Nov 2017
- Last trade
- 23 Feb 2026
- Last filed
- 24 Feb 2026
Companies traded
Activity over time
1 May 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Feb 2026filed 24 Feb 2026 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —375,000 at $0.00 | filing |
| 23 Feb 2026filed 24 Feb 2026 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —375,000 at $0.00 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code D | —180,995 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —180,995 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code D | —180,995 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —180,995 | filing |
| 21 May 2025filed 22 May 2025 | PRME Prime MedicineBiotechnology | SEC FORM 4 Bought | $113K100,000 at $1.13 | filing |
| 8 May 2025filed 12 May 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,416 at $0.00 | filing |
| 27 Feb 2025filed 3 Mar 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —275,000 at $0.00 | filing |
| 17 May 2024filed 21 May 2024 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,416 at $0.00 | filing |
| 21 Feb 2024filed 23 Feb 2024 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —180,995 at $0.00 | filing |
| 31 Mar 2023filed 4 Apr 2023 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —180,995 at $0.00 | filing |
| 5 Mar 2018filed 7 Mar 2018 | Juno Therapeutics | SEC FORM 4 Code D | —35,004 | filing |
| 5 Mar 2018filed 7 Mar 2018 | Juno Therapeutics | SEC FORM 4 Code D | —40,788 | filing |
| 5 Mar 2018filed 7 Mar 2018 | Juno Therapeutics | SEC FORM 4 Code D | —35,000 | filing |
| 5 Mar 2018filed 7 Mar 2018 | Juno Therapeuticsoption or derivative | SEC FORM 4 Code D | —152,900 | filing |
| 31 Jan 2018filed 2 Feb 2018 | Juno Therapeutics | SEC FORM 4 Code A | —40,788 at $0.00 | filing |
| 25 Nov 2017filed 28 Nov 2017 | Juno Therapeutics | SEC FORM 4 Code A | —35,004 at $0.00 | filing |
| 25 Nov 2017filed 28 Nov 2017 | Juno Therapeutics | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 25 Nov 2017filed 28 Nov 2017 | Juno Therapeuticsoption or derivative | SEC FORM 4 Code A | —152,900 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.